Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
QiJiong Li, Minke He, Huanwei Chen, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 2, pp. 150-160
Closed Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 189
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 88
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 80
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jie-Yi Shi, Jian Zhou, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 2, pp. 206-216
Open Access | Times Cited: 71
PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
Yunxing Shi, Yi Niu, Yichuan Yuan, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 54
Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
Tianqi Zhang, Zhijun Geng, Mengxuan Zuo, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 52
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis
Yizhen Fu, Wei Peng, Weixiang Zhang, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 4, pp. 413-424
Closed Access | Times Cited: 40
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 24
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 10
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Yonglin Hua, Zhixian Sun, Yuxin Xiao, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008953-e008953
Open Access | Times Cited: 10
Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitiors for unresectable hepatocellular carcinoma and meta-analysis
Yu-Zhe Cao, Guang-lei Zheng, Tianqi Zhang, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 4, pp. 318-331
Open Access | Times Cited: 9
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis
Shun-An Zhou, Qing-Mei Zhou, Lei Wu, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 8, pp. 3672-3686
Open Access | Times Cited: 8
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
Qiao Ke, Fuli Xin, Huipeng Fang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma
Xiaofeng Kang, Yan Huo, Songhao Jia, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 35
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Yujing Xin, Fei Cao, Hongcai Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Renguo Guan, Jie Mei, Wen‐Ping Lin, et al.
Hepatology International (2023) Vol. 17, Iss. 5, pp. 1279-1288
Closed Access | Times Cited: 16
A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy
Xuelei He, Kai Li, Ran Wei, et al.
La radiologia medica (2023) Vol. 128, Iss. 12, pp. 1508-1520
Open Access | Times Cited: 16
Magnetic Metal–Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma
Hong Guo, Yuping Liu, Xia Li, et al.
ACS Nano (2023) Vol. 17, Iss. 23, pp. 23829-23849
Open Access | Times Cited: 16
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment
Zhenyun Yang, Xin Wang, Yizhen Fu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate
Qifeng Chen, Song Chen, Minshan Chen, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 6
Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma
YeXing Huang, ZeFeng Du, Anna Kan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study
Yi‐Xiang Gan, Ziliang Yang, Yangxun Pan, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 6
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
Yufeng Zhang, Haiyan Zhang, Haoqian Xu, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
TRIM28 in cancer and cancer therapy
Kailang Li, Haifeng Wang, Bitao Jiang, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 6
m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma
Lin Zhu, Zhenkun Huang, Jiliang Qiu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top